University of North Carolina

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

Retrieved on: 
水曜日, 2月 7, 2024
Traffic barrier, Sanfilippo, Genomics, Hearing, Growth, BBB, AFL, Metabolism, Feinberg School of Medicine, Spleen, Dermatan sulfate, Patient, Cerebrospinal fluid, University of North Carolina, FDA, Cognition, COMPASS, Mouse, CSF, Physician, Hunter syndrome, MPS II, Brain, Behavior, MPS, Mucopolysaccharidosis, Hunting, University, SGSH, ETV, Liver, Alfa, Glycogen storage disease, Pharmaceutical industry

Denali’s BBB-crossing enzyme replacement approach has the potential to prevent cognitive and behavioral manifestations in MPS IIIA.

Key Points: 
  • Denali’s BBB-crossing enzyme replacement approach has the potential to prevent cognitive and behavioral manifestations in MPS IIIA.
  • New two-year peripheral biomarker data demonstrate high magnitude and sustained reduction of urine heparan sulfate and dermatan sulfate, including in participants who switched from standard-of-care enzyme replacement therapy to tividenofusp alfa, suggesting enhanced peripheral activity.
  • Denali also announced that dosing has begun in the Phase 1/2 study of DNL126 for the potential treatment of MPS IIIA.
  • “Our goal is to bring effective new medicines to MPS families as soon as possible,” said Carole Ho, M.D., Chief Medical Officer of Denali.

Season 2 of "Car Wash Convos™" Features Texas Men's Basketball Forward Brock Cunningham

Retrieved on: 
火曜日, 1月 30, 2024
University of Memphis, App Store (iOS/iPadOS), University of North Carolina, Life, University, Female, Athlete, Male, NIL, Longhorn, Learfield, Basketball, University of Georgia, Personality, University of Tennessee, Brock

AUSTIN, Texas, Jan. 30, 2024 /PRNewswire/ -- ZIPS "Car Wash Convos™" is back in Austin this week with another ride-along interview featuring Texas Longhorns Men's Basketball forward, Brock Cunningham.

Key Points: 
  • AUSTIN, Texas, Jan. 30, 2024 /PRNewswire/ -- ZIPS "Car Wash Convos™" is back in Austin this week with another ride-along interview featuring Texas Longhorns Men's Basketball forward, Brock Cunningham.
  • Brock's episode was filmed with his host, Texas alum, Ray Villareal, during a car wash at ZIPS in Austin and was released today on YouTube and Instagram.
  • "I love sharing more of my personality with Longhorn Nation and I'm proud to represent my team and my school in this unique approach to NIL," said Brock Cunningham, Texas Longhorns forward.
  • He is currently in his sixth season on the Texas Longhorns Men's Basketball team and has played in 113 career games.

GeneCentric Therapeutics Announces Upcoming Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium and Precision Medicine World Conference

Retrieved on: 
月曜日, 1月 22, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Patient, Carcinoma, Therapy, University of North Carolina, RNA, ASCO, University, Society, Conference, Medicine, Pharmaceutical industry

GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced upcoming presentations at the Precision Medicine World Conference (PMWC) in Santa Clara, California from January 24-26 and the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), which will be held January 25-27 in San Francisco, California.

Key Points: 
  • GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced upcoming presentations at the Precision Medicine World Conference (PMWC) in Santa Clara, California from January 24-26 and the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), which will be held January 25-27 in San Francisco, California.
  • “We are encouraged to see the growing adoption of our signatures and tests by commercial reference labs and biopharma partners leading the way in precision oncology."
  • GeneCentric will present at PMWC, which was established in 2009 and is the largest annual conference dedicated to precision medicine.
  • GeneCentric’s presentations will highlight the use of transcriptomics in precision medicine and the development of RNA-based diagnostics.

H2O.ai Launches GenAI World in Atlanta to Bring Education and Awareness of Responsible AI and Guardrails for Safety, Fairness and Privacy for Generative AI in Banking

Retrieved on: 
月曜日, 1月 22, 2024
White House, Federal Government, Thought Leadership, Telecommunications, Software, Artificial Intelligence, Finance, Banking, Data Management, Professional Services, Technology, Online Privacy, Fintech, Public Policy, Government, Personal Finance, Data Analytics, University, Training, Education, Risk management, Research, AT&T, Document AI, Enterprise, Safety, Computing, Gen, Good, PNC, Health, Wells Fargo, Assistant, School, Machine learning, Privacy, University of North Carolina, Computational science, City, Progressive Corporation, SlideShare, Generative, Movement, Responsibility, Data science, University of Michigan, Financial services, Head, AES, Guard rail, AI, Georgia Tech, University of Georgia, Synthetic media, Engineering, Commonwealth Bank, PayPal, Multimedia, Bank, Bias, Document, Conference, Toxicity, ADP, Medical device

H2O.ai, the open source leader in Generative AI and machine learning, continues its world tour of bringing GenAI Training Days to major cities around the world to further democratize GenAI.

Key Points: 
  • H2O.ai, the open source leader in Generative AI and machine learning, continues its world tour of bringing GenAI Training Days to major cities around the world to further democratize GenAI.
  • Join David Palmer , Neil Desai , and Loren Bushkar as they explore the ethical, practical, and regulatory aspects of AI throughout the finance sector and more.
  • Join H2O.ai Makers to learn about Responsible AI and Guardrails for Safety, Fairness, and Privacy in Generative AI for banking.
  • Founded in 2012, H2O.ai is at the forefront of the AI movement to democratize Generative AI.

Focal Medical Receives FDA Clearance to Initiate Phase 1b Clinical Trial of ACT-IOP-003, a Targeted Therapeutic Product in Development for Pancreatic Cancer

Retrieved on: 
火曜日, 1月 9, 2024
Research, Professional Services, Pharmaceutical, Oncology, Venture Capital, Medical Devices, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, ACT, Hope, Pancreatic cancer, Investigational New Drug, Neoplasm, Patient, Incidence, University of North Carolina, Professor, Multimedia, Food and Drug Administration, Survival, University, IND, Food, Safety, Disease, Medicine, LANR, Toxicity, American Cancer Society, Clinical trial, Pancreas, Pharmaceutical industry

Focal Medical, Inc., (“Focal”) a privately held biopharmaceutical company developing a targeted therapeutic system to treat inoperable tumors and to deliver genomic medicines, today announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application to initiate a Phase 1b clinical trial of ACT-IOP-003, the Company’s first targeted therapeutic product.

Key Points: 
  • Focal Medical, Inc., (“Focal”) a privately held biopharmaceutical company developing a targeted therapeutic system to treat inoperable tumors and to deliver genomic medicines, today announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application to initiate a Phase 1b clinical trial of ACT-IOP-003, the Company’s first targeted therapeutic product.
  • The trial will evaluate the safety and tolerability of targeted delivery of gemcitabine to locally advanced nonresectable (LANR) pancreatic tumors.
  • According to The American Cancer Society, the incidence of pancreatic cancer in the U.S. is more than 62,000 cases annually and it represents the third leading cause of cancer death.
  • The multi-center, open label, modified dose escalation phase 1b clinical trial will assess the safety, tolerability, and clinical activity of the implantable ACT-IOP-003 targeted therapeutic product delivering gemcitabine directly into the pancreas to treat LANR pancreatic cancer.

Paytronix Appoints Eric Steele as Chief Financial Officer

Retrieved on: 
木曜日, 1月 4, 2024
Restaurant, CFO, Business administration, University, Corporate development, University of North Carolina, Senior

NEWTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Paytronix, the leading digital guest engagement platform for restaurants and convenience stores , today announced that Eric Steele has been appointed company Chief Financial Officer.

Key Points: 
  • NEWTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Paytronix, the leading digital guest engagement platform for restaurants and convenience stores , today announced that Eric Steele has been appointed company Chief Financial Officer.
  • Eric replaces acting CFO Lee Barnes, who will continue to serve as Paytronix Chief Data Officer and take on additional responsibility as Chief of Staff.
  • Eric joins Paytronix from Snap One, where he played a key role in scaling the business to a public company with more than $1 billion in revenue.
  • He understands the value drivers to build enduring businesses, making him the perfect person to help us scale Paytronix for the future.”
    “I'm thrilled to join Paytronix and advance our industry leadership position in digital guest engagement,” said Eric Steele, CFO, Paytronix.

ACTG Announces Launch of Clinical Trial Evaluating Novel Treatment for Tuberculous Meningitis

Retrieved on: 
木曜日, 12月 7, 2023
TBM, Infection, NIAID, Tuberculous meningitis, Research, Vanderbilt University, DRS, University of California, Mortality, Spinal cord, Ageing, Membrane, Brain, Pyrazinamide, Linezolid, UM1, Inflammation, University, HIV, Bangladesh Technical Education Board, Tuberculosis, University of North Carolina, ACTG, Rifampicin, Pharmaceutical industry

LOS ANGELES, Dec. 07, 2023 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the IMAGINE-TBM study (Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM, also known as A5384). IMAGINE-TBM is a phase 2, randomized, open-label trial comparing a six-month regimen of high-dose rifampicin, high-dose isoniazid, linezolid, and pyrazinamide to the nine-month standard-of-care regimen for the treatment of tuberculous meningitis.

Key Points: 
  • IMAGINE-TBM is a phase 2, randomized, open-label trial comparing a six-month regimen of high-dose rifampicin, high-dose isoniazid, linezolid, and pyrazinamide to the nine-month standard-of-care regimen for the treatment of tuberculous meningitis.
  • Tuberculous meningitis is a life-threatening infectious disease that causes inflammation of the membranes that surround the brain and spinal cord.
  • Even with standard-of-care treatment, outcomes are poor, with high rates of mortality and chronic disability among those who survive.
  • ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice-Chair).

New to The Street's Leadership Series Features University of North Carolina's Anson Dorrance, Head Coach of the Women's Soccer Team, and Kevin Guskiewicz, University Chancellor; Televised Interviews Air on Bloomberg TV as Sponsored Programming on Saturday

Retrieved on: 
金曜日, 11月 24, 2023
Soccer Team (band), FS, TIME, University, Athlete, Business, First, Student, Trustee, Politics, Parent, Concussion, NCAA, UNC, Doctor of Philosophy, Chancellor (education), Education, College, Football, Dean, National Collegiate Athletic Association, Bloomberg Television, NFL, The arts, Optimism, Organization, University of North Carolina, Public good, Algorithm, Chancellor, Creativity, MacArthur Fellows Program, Child

As the most successful coach in UNC's athletic history, Anson won 1093 games during his 47 years as a coach.

Key Points: 
  • As the most successful coach in UNC's athletic history, Anson won 1093 games during his 47 years as a coach.
  • In 1974, Coach Dorrance graduated from UNC, and soon after, became a coach at UNC, becoming the head coach for the men's soccer team in 1977.
  • Matt shares with viewers that he remembered Coach Dorrance's commitment to excellence during his student-athlete years at UNC.
  • Coach Dorrance shares his leadership successes as a coach and mentor for the UNC athletes on his teams.

Mojdeh Poul and Kevin Conroy Join Align Technology Board of Directors

Retrieved on: 
火曜日, 12月 5, 2023
Electronic Design Automation, Medical Devices, Health, Technology, Dental, Software, Align Technology, Private practice, SomaLogic, Boston Scientific, Mechanical engineering, Medtronic, Electrical engineering, Stanley Black, 3M, Michigan State University, Multimedia, FDA, GE HealthCare, Annual general meeting, Exact sciences, EVP, Electricity, University, Growth, Medicare, University of North Carolina, Research, Knowledge, ALGN, Mechanical, Align, Management, Decker

Align Technology, Inc. (NASDAQ: ALGN) today announced that its Board of Directors has appointed Mojdeh Poul, former EVP and Group President of 3M Health Care, and Kevin Conroy, President, Chief Executive Officer, and Chairman of the Board of Exact Sciences.

Key Points: 
  • Align Technology, Inc. (NASDAQ: ALGN) today announced that its Board of Directors has appointed Mojdeh Poul, former EVP and Group President of 3M Health Care, and Kevin Conroy, President, Chief Executive Officer, and Chairman of the Board of Exact Sciences.
  • View the full release here: https://www.businesswire.com/news/home/20231205333071/en/
    Image of Mojdeh Poul (Photo: Business Wire)
    “I am pleased to welcome Mojdeh and Kevin to Align’s board of directors,” said Joe Hogan, president and CEO of Align Technology.
  • Kevin Conroy is President, Chief Executive Officer, and Chairman of the Board of Exact Sciences Corporation.
  • Align’s board is comprised of 10 directors, four of whom will have been appointed in the last six years.

YuJa, Inc. Announces Partnership with Project Kitty Hawk to Serve Adult Learners in North Carolina

Retrieved on: 
火曜日, 11月 28, 2023
Software, Internet, Audio, Video, Other Education, Continuing, Technology, University, Education, University of North Carolina, Student, LMS, Family, Tutoring, Mathematics, Science, Yuzu

YuJa, Inc., a leader in ed-tech solutions, announces an agreement with Project Kitty Hawk (PKH), a nonprofit ed-tech startup that is partnering with University of North Carolina System institutions to better serve adult learners.

Key Points: 
  • YuJa, Inc., a leader in ed-tech solutions, announces an agreement with Project Kitty Hawk (PKH), a nonprofit ed-tech startup that is partnering with University of North Carolina System institutions to better serve adult learners.
  • PKH helps universities deliver workforce-aligned online degree programs that are geared specifically toward adult learners.
  • “Because adult learners are often trying to balance work and family with their education, they prefer an asynchronous learning environment.
  • Having tools like YuJa are essential to providing the best-in-class learning experience that North Carolina adult learners deserve.”